Citations

Showing 10 of 108081 citations.

Personality Disorders in Primary Care: Impact on Depression Outcomes Within Collaborative Care
Angstman, Kurt B. , Seshadri, Ashok , Marcelin, Alberto, González, César A. , Garrison, Gregory M. , Allen, Jay-Sheree , Gonzalez, Cesar

Mayo Clinic

Journal of Primary Care & Community Health | June 14, 2017 | Volume: 8 | Issue: 4 | Pages: 233-238

10.1177/2150131917714929 | PMID 28613090 Get It

Background:Individuals with personality disorders (PDs) are high utilizers of primary care and mental health services; however, they struggle to utilize the care effectively and studies have shown a strong association between having a PD and higher impairment in social role functioning. This is especially important because PDs are highly comorbid with a wide range of other mental health disorders. The collaborative care model (CCM) for depression was developed with an emphasis on patient engagement and aimed to reduce health care utilization, while improving treatment outcomes in primary care. We hypothesized that the diagnosis of a personality disorder in primary care patients will negatively affect 6-month depression outcomes after enrollment into a CCM. Methods: This retrospective chart review study was conducted on patients enrolled into CCM over a period of 7 years with collection of 6-month follow-up data. A total of 2826 patients were enrolled into CCM with a clinical diagnosis of depression and a baseline Patient Health Questionnaire–9 (PHQ-9) ≥10 were included in the study cohort. Using the depression database, baseline and 6-month follow-up data were obtained. Adjusted odds ratios (AORs) were determined for both remission and persistent depressive symptoms using logistic regression modeling for the 6-month PHQ-9 outcome; while retaining all the study variables. Results: Of the 2826 CCM patients with depression in our study, 216 (7.6%) were found to have a PD. Patients with PD were younger (37.7 vs 42.5 years, P < .001) and more likely to be unmarried (36.1% vs 55.6%, P < .001) than patients without a PD. While age, marital status, clinical diagnosis, and Mood Disorders Questionnaire (MDQ) score were significant predictors of remission; anxiety symptoms, gender, and race were not. The presence of a PD diagnosis was associated with a 60% lower likelihood of remission at 6 months (AOR = 0.39; 95% CI 0.28-0.54). Conversely, patients without a PD were 2.5 times as likely to experience remission at 6-month remission compared to patients with PD (AOR =2.57; 95% CI 1.85-3.56). Conclusion: Patients with a personality disorder were more likely to have a recurrent depressive disorder diagnosis, an abnormal MDQ score, increased anxiety symptoms, and higher baseline PHQ-9 score. Patients with PD had worse CCM outcomes at 6 months with only 25.0% able to achieve remission versus 54.3% ( P < .001) without a PD. The presence of a PD with depression was associated with poor outcomes (reduced remission rates and increased persistent depressive symptoms rates) in comparison to patients without a diagnosis of PD, while treated within CCM.
Response to Letter by Friedman on “Incidence and time trends of drug‐induced parkinsonism: A 30‐year population‐based study”
Rocca, Walter A. , Savica, Rodolfo , Grossardt, Brandon R.

Mayo Clinic

Movement Disorders | June 14, 2017 | Volume: 32 | Issue: 7 | Pages: 1111-1112

10.1002/mds.27051 | PMID 28612941 Get It

Faculty Opinions recommendation of Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study.
Huebert, Robert C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727687873.793532957 Get It

The impact of transferred vascularized toe joint length on motion arc of reconstructed finger proximal interphalangeal joints: a cadaveric study
Hsu, Chung‐Chen , Loh, Charles Yuen Yung , Kao, Dennis S. , Moran, Steven L. , Lin, Yu‐Te

Mayo Clinic

Journal of Hand Surgery (European Volume) | June 14, 2017 | Volume: 42 | Issue: 8 | Pages: 789-793

10.1177/1753193417714207 | PMID 28610461 Get It

Vascularized toe joint transfer for finger proximal interphalangeal joint reconstruction can result in sub-optimal arc of motion and extension lag due to inappropriate intercalated bony segment length. We investigated the impact of intercalated segment length on passive arc of motion and extension lag of the reconstructed proximal interphalangeal joint. Cadaveric intercalated joint grafts were harvested from lesser toes and transferred to cadaveric fingers. The pre-determined finger proximal interphalangeal joint defect size was 2 cm. Three different intercalated segment lengths were inserted and resulting proximal interphalangeal joint arc of motion and extension lag were measured. The average arc of motion of finger proximal interphalangeal joints was 81° and 54° for toe proximal interphalangeal joints. Long intercalated segments had an average arc of motion of 30° with 32° extension lag. Equal-length intercalated segments had an average 49° arc of motion with 15° extension lag. Short intercalated segments had an average arc of motion of 71° with 8° extension lag. Shorter intercalated segments provide the greatest reduction in extension lag.
Composite cryogels for dual drug delivery and enhanced mechanical properties
Lima, Gabriel Goetten de , Traon, Fanny , Moal, Elouan, Pérez, María Canillas , Rodríguez, Miguel Á. , McCarthy, Helen O. , Dunne, Nicholas , Devine, Declan M. , Nugent, Michael , de Lima, Gabriel G

Mayo Clinic

Polymer Composites | June 13, 2017 | Volume: 39 | Issue: S1 | Pages: No page available

10.1002/pc.24450 Get It

In this study, we present a simple and effective process that integrates hydrogels with drugs + ceramics via physical crosslinks resulting in improved mechanical properties. These cryogels have the potential for controlled drug release and stimulus responsive behavior. The hydrogels were produced from polyvinyl alcohol (PVA) and polyacrylic acid by varying the molecular weight of the polymers, via freeze‐thawing technique. The cryogels were combined with two ceramics: (1) a combination of beta‐tricalcium phosphate, wollastonite, magnesium silicate and (2) titanium dioxide nanopowder. Theophylline, a model drug, was incorporated into the structure to analyze the drug release behavior. A layered structure was produced by adding both hydrogels + ceramics into a mold where a PVA dried film acted as a barrier and reinforcing structure. The results showed that the barrier integrated between both hydrogels by a physically crosslinking mechanism. This adhesion was demonstrated using Fourier‐transform infrared spectroscopy and scanning electron microscopy. Swelling of this composite showed the profile of drug release from both hydrogels + ceramics while simultaneously releasing the drug independently without diffusing via the opposite layer. Finally, mechanical properties were improved with the addition of the ceramics, which demonstrates the potential approach in terms of modification of weak hydrogel systems. POLYM. COMPOS., 39:E210–E220, 2018. © 2017 Society of Plastics Engineers
Effect of a Motivational Interviewing-Based Health Coaching on Quality of Life in Subjects With COPD
Rehman, Hamid, Karpman, Craig, Douglas, Kristin Vickers, Benzo, Roberto P. , Vickers Douglas, Kristin

Mayo Clinic

Respiratory Care | June 13, 2017 | Volume: 62 | Issue: 8 | Pages: 1043-1048

10.4187/respcare.04984 | PMID 28611230 Get It

BACKGROUND: Improving quality of life (QOL) is a key goal in the care of patients with COPD. Pulmonary rehabilitation (PR) has clearly been shown to improve QOL, but is not accessible to many eligible patients. There is a need for alternative programs designed to improve patient well-being that are accessible to all patients with COPD. Our goal was to pilot test a simple, telephone-based health-coaching intervention that was recently shown to decrease readmission among hospitalized COPD patients and stable COPD patients eligible for PR. METHODS: Subjects received a 3-month intervention consisting of 10 health-coaching telephone calls based on motivational interviewing principles. Outcome measures included dyspnea level, measured by the modified Medical Research Council scale, and QOL, measured by the Chronic Respiratory Questionnaire and a single-item general self-rated health status. RESULTS: Fifty subjects with moderate to severe COPD were enrolled in the study. Forty-four subjects (86%) completed the study intervention. Dyspnea measured by the modified Medical Research Council score improved significantly after the intervention ( P = .002). The domains of fatigue, emotional function, and mastery on the Chronic Respiratory Disease Questionnaire and the single-item QOL question also improved significantly after the 3 months of health coaching ( P = .001, P = .001, P = .007, and P = .03, respectively). Thirty-six (71%) subjects had a clinically meaningful improvement in at least 1 study end point (either in the severity of dyspnea or a domain of QOL). Thirty subjects (58%) had an improvement of ≥0.5 points, the minimum clinically important difference in at least 1 component of the Chronic Respiratory Disease Questionnaire. CONCLUSIONS: A telephone-delivered motivational interviewing-based coaching program for COPD patients is a feasible, well-accepted (by both participants and providers), simple, and novel intervention to improve the well-being of patients with COPD. This pilot study provides insight into a possible alternative to a conventional PR program for patients with limited access to that program.
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
Donohue, Michael , Petersen, Ronald C. , Sun, Chung‐Kai , Weiner, Michael W. , Aisen, Paul , Initiative, for the Alzheimer’s Disease Neuroimaging, Sperling, Reisa Anne , Initiative, for the Alzheimer’s Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

JAMA | June 13, 2017 | Volume: 317 | Issue: 22 | Pages: 2305

10.1001/jama.2017.6669 | PMID 28609533 Get It

Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow preserved ejection fraction aortic stenosis
Benfari, Giovanni , Clavel, Marie‐Annick , Nistri, Stefano , Maffeis, Caterina , Vassanelli, Corrado , Enriquez‐Sarano, Maurice , Rossi, Andrea , Enriquez-Sarano, Maurice , Benfari, Giovanni , Clavel, Marie-Annick , Nistri, Stefano

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 13, 2017 | Volume: 19 | Issue: 5 | Pages: 569-573

10.1093/ehjci/jex172 | PMID 28950322 Get It

Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.
Basch, Ethan , Deal, Allison M. , Atkinson, Thomas M. , Scher, Howard I. , Hudis, Clifford A. , Sabbatini, Paul , Rogak, Lauren J. , Leahy, Allison Barz , Basch, Ethan , Deal, Allison , Dueck, Amylou C. , Bennett, Antonia V , Kris, Mark G. , Dulko, Dorothy , Schrag, Deborah , Leahy, Allison B

Mayo Clinic

Journal of Clinical Oncology | June 13, 2017 | Volume: 35 | Issue: 18_suppl | Pages: LBA2-LBA2

10.1200/jco.2017.35.18_suppl.lba2 Get It

LBA2 Background: We previously reported significant benefits in quality of life, patient satisfaction, and emergency room utilization outcomes from a large single-center randomized controlled trial comparing web-based symptom monitoring with patient-reported outcomes (PROs) vs. usual care in patients receiving chemotherapy for metastatic solid tumors (Clinicaltrials.gov: NCT00578006). We now present overall survival results from this trial. Methods: Patients receiving routine outpatient chemotherapy for metastatic solid tumors at Memorial Sloan Kettering Cancer Center were randomly assigned to self-report 12 common symptoms via tablet computers (“PRO intervention”), or to usual care. Treating physicians received symptom printouts at visits and nurses received email alerts when participants reported severe or worsening symptoms. Overall survival was tabulated based on medical records and Social Security Death Index data, estimated using the Kaplan-Meier method, and compared between arms using a log-rank test and Cox proportional hazards regression adjusting for age, sex, race, education level, and cancer type. Results: Between September 2007 and January 2011, 766 patients were randomized, with median age 61 (range 26-91), 86% white, 58% female, and 22% with less than high school education. Cancer types included genitourinary (32% of patients), gynecologic (23%), breast (19%), and lung cancer (26%). Survival results were assessed in June 2016 after a median follow up of 7 years and 517/766 (67%) of participants had died. Median overall survival in the PRO intervention arm was 5 months longer than the control arm (31.2 vs. 26.0 months, p = 0.03). In the multivariable model, results remained statistically significant with a hazard ratio of 0.832 (p = 0.04; 95% CI; 0.696, 0.995). Conclusions: Systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes confers overall survival benefits. These single-center results are being further evaluated in a national multicenter implementation trial. Clinical trial information: NCT00578006.
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemothera
Sobrero, Alberto F. , Shields, Anthony F. , Sougklakos, Ioannis, Bonnetain, Franck, Watanabe, Toshiaki , Boukovinas, Ioannis , Renfro, Lindsay A. , Grothey, Axel, Niedzwiecki, Donna , Shi, Qian , Yoshino, Takayuki , Paul, James , Taı̈eb, Julien , Kerr, Rachel , Labianca, Roberto , Meyerhardt, Jeffrey A. , Torri, Valter , André, Thierry , Sargent, Daniel J. , Iveson, Timothy , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | June 13, 2017 | Volume: 35 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2017.35.18_suppl.lba1 Get It

LBA1 Background: Since 2004, 6 months (m) of oxaliplatin (oxali)-based treatment has been the standard of care as adjuvant therapy for stage III CC. Since oxali is associated with cumulative neurotoxicity, shorter duration of adjuv therapy could spare pts toxicity and lead to substantial saving in health expenditures. Methods: A prospective, pre-planned pooled analysis of 6 concurrently conducted randomized phase III trials (SCOT, TOSCA, Alliance/SWOG 80702, IDEA France (GERCOR/PRODIGE), ACHIEVE, HORG) was performed to evaluate the non-inferiority (NI) of 3m compared with 6m (ref) of adjuv FOLFOX/XELOX. The primary endpoint was disease-free survival (DFS), defined as time from enrolment to relapse, 2nd CRC, and death (all causes). NI was to be declared if the 2-sided 95% confidence interval (CI) for DFS hazard ratio (HR 3m v 6m) estimated by a stratified Cox model was below 1.12. NI was examined within regimen and stage subgroups as pre-planned. Results: The analysis included 12,834 pts from 12 countries, accrued from 6/07 to 12/15. Stage distribution: 13% T1-2, 66% T3, 21% T4; 28% N2; 40% received XELOX. G3+ neurotoxicity was higher in the 6m v 3m arm (16 v 3% FOLFOX, 9 v 3% XELOX, p<0.0001). With a median follow-up of 39 mos, 3263 DFS events were observed. Overall, the 3 year DFS rate was 74.6% (3m) and 75.5% (6m), with estimated DFS HR of 1.07 (95%CI, 1.00-1.15). The 3m v 6m DFS HRs were 1.16 (95%CI, 1.06-1.26) and 0.95 (95% CI, 0.85-1.06) for FOLFOX and XELOX treated pts, respectively. The 3m v 6m DFS HRs were 1.01 (95%CI, 0.90-1.12) in T1-3 N1, and 1.12 (95%CI, 1.03-1.23) for T4 or N2 pts. Conclusions: While NI was not established for the overall cohort, NI of 3m v 6m oxali-based adjuv therapy was supported for XELOX. As each IDEA trial treated varying proportions of pts with XELOX (0 to 75%), the regimen interaction likely produced the differential outcomes observed between individual studies. Certain substages (T1-3 N1) also showed NI for 3m v 6m. These data provide a framework for discussions on risks and benefits of individualized adjuv therapy approaches. Support: U10CA180821, U10CA180882, U10CA180888, U10CA180835, INCA, PHRC2009, EME 09/800/34, HTA 14/140/84, CRUK C1348/A15960, JFMC. Clinical trial information: NCT01150045.